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spina bifida. In studies of births in Great Britain prior
to 1979, the prevalence of spina bifida at birth was
within the range of 1.5–4.1 per 1,000 births, and, in
studies in the early 1980s, the prevalence was within the
range of 0.7–1.9 per 1,000 births (Little and Elwood
1992). Some of these infants would have been stillborn.
For example, in Northern Ireland during the period
1974–79, 15.5% of 569 cases of spina bifida or encepha-
lacoele were stillborn (Little and Nevin 1989). In Glas-
gow and Liverpool during the period 1980–92, when
fetuses from terminated pregnancies were excluded,
16% of 262 cases of spina bifida were recorded to have
resulted in fetal deaths (EUROCAT Working Group
1995). Therefore, it appears that the proportion of cases
of childhood cancer with neural tube defects is similar
to what would be expected on the basis of data on the
prevalence of these defects at birth, in Great Britain.
In the study by Narod et al. (1997), eight of the chil-
dren with tumors of the brain or of the spinal cord were
recorded as having spina bifida, compared with the 5.6
expected on the basis of the frequency of spina bifida
among children with other types of cancer in Great Brit-
ain and with the 2.4 expected on the basis of the data
for British Columbia. Again, the proportion of children
with tumors of the brain or of the spinal cord who were
recorded as having spina bifida (1.7 per 1,000 births)
would appear to be within the range of prevalences at
birth reported for Great Britain during the period in
which the children included in the study by Narod et al.
would have been born. Thus, the study by Narod et al.
does not appear to support the hypothesis of a common
maternal factor for brain tumors and spina bifida.
JULIAN LITTLE
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University of Aberdeen
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Reply to Little
To the Editor:
My colleagues and I thank Dr. Little (1997 [in this issue])
for his important data. We saw an excess of neural tube
defects in children with cancer, in the United Kingdom,
compared with healthy controls from British Columbia.
It is unclear to what extent the control group from Brit-
ish Columbia was comparable to the children from Brit-
ain, and our approach is inadequate when the baseline
rates of disease differ for the two countries. Unlike the
rates of other malformations, the rate of spina bifida
was not significantly greater in children with solid tu-
mors than in those with leukemia. We agree that our
data do not allow us to conclude that there is an excess
of cancer among children with neural tube defects.
STEVEN NAROD
The Centre for Research in Women’s Health
Toronto
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Lafora Progressive Myoclonus Epilepsy: Narrowing
the Chromosome 6q24 Locus by Recombinations
and Homozygosities
To the Editor:
Lafora disease (LD) is an autosomal recessive and rare
but fatal epilepsy syndrome characterized by stimuli-sen-
sitive myoclonus, absence and grand mal seizures, pro-
gressive intellectual and neurological deterioration, and
periodic acid Schiff (PAS) stain–positive intracellular in-
clusion bodies. Eighty-four years after Gonzalo Lafora
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(1911a, 1911b) first described such PAS-positive “intra-
cellular amyloid bodies” in the CNS of a young adult
who died from a progressive myoclonus epilepsy, we
encountered extended areas of homozygosities in chro-
mosome 6q23-25 in nine LD patients whowere products
of consanguineous marriages (families LD1, LD4, LD5,
and LD9). We also detected significant linkage to chro-
mosome 6q23-25 microsatellites in one large inbred
family, LD9, and thus localized the LD gene to a 17-cM
interval on chromosome 6q23-25, between D6S292 and
D6S420 (Serratosa et al. 1995).
To reduce the size of the 17-cM candidate region, we
have studied an expanded series of 39 biopsy-proved LD
patients who belong to 26 unrelated families (12 inbred)
from Spain, Canada, France, the United States, Palestine,
Iran, Ecuador, and Saudi Arabia. We provide further
proof for significant linkage of LD to chromosome 6q24
in a second and new large inbred family (LD33). Ho-
mozygosities and recombinations in six new informative
families reduce the size of the previously reported 17-
cM LD interval to 2.7 cM flanked centromerically by
D6S1003 and telomerically by D6S311.
The clinical diagnosis of LD was initially established
by the referring physician and was corroborated by the
senior epileptologist in this study. PAS-positive inclusion
bodies were demonstrated in skin and/or muscle and in
liver and/or brain biopsies of all affected family mem-
bers, including affected individuals carrying recombi-
nant chromosomes. High-molecular-weight DNA was
extracted either from 10 ml of venous blood from living
family members, by use of phenol/chloroform followed
by isopropanol precipitation (Sambrook et al. 1989), or
from 200 ml of peripheral blood by use of the QUIAamp
blood kit (Qiagen). DNA from deceased familymembers
(LD9-10, LD9-12, LD9-16, LD18-3, and LD19-3) was
extracted from paraffin-embedded archived autopsy
specimens of liver, brain, and muscle (Jackson et al.
1990; Greer et al. 1991). All primers for amplification
were obtained from Research Genetics. The method of
Weber and May (1989) was used to type highly poly-
morphic short tandem repeats or microsatellites (het-
erozygosity 1.7) in 50 parents and in 39 affected and
56 unaffected individuals.
Parametric or model-dependent two-point linkage
analyses using LINKAGE 5.1 (Ott 1974) were per-
formed in eight multiplex families (LD3, LD4, LD6,
LD9, LD12, LD27, LD28, and LD33) and in five sim-
plex consanguineous families (LD1, LD5, LD7, LD22,
and LD25). We estimated the frequency of the disease
allele to be .001, and penetrance was set at 100%, as-
suming an autosomal recessive model. The gene muta-
tion rate was set at 0. We calculated LOD scores at
recombination fractions (vmf).We performedmultipoint
linkage analyses in family LD33, using a new software
package, GENEHUNTER (Kruglyak et al. 1996).
We first looked for recombinations and homozygos-
ities (Lander and Botstein 1987) in families LD9 and
LD33, because they provided independent proof for
linkage to chromosome 6q24. We had previously pub-
lished significant LOD scores obtained during two-point
analyses in family LD9 (Serratosa et al. 1995). We used
the new generation of microsatellites in family LD9 but
did not reduce the size of the 17-cM LD region, flanked
centromerically by D6S292 and telomerically by
D6S420, that we had reported in 1995.
In family LD33, the LOD score for D6S1703 was 3.24
(vmf  0) during two-point analyses (Ott 1974), ex-
ceeding the threshold for significance. We also computed
10-point LOD scores (Kruglyak et al. 1996) in family
LD33, against a fixed genetic map with nine markers
(D6S308, D6S409, D6S1003, D6S1010, D6S1703,
D6S1042, D6S311, D6S978, and D6S420) in an 11-cM
region surrounding the LD gene. During multipoint
analysis, we obtained maximum location scores of 4.03
for markers D6S1010, D6S1703, and D6S1042, which
are situated between D6S1003 and D6S311.
Recombinations and homozygosities in LD33 were
consistent with results of two-point and multipoint anal-
yses and reduced the size of the LD-gene region to the
interval flanked by D6S1003 and D6S1687 (fig. 1).
Homozygosities in all three living affected members (see
haplotypes of LD33-3, LD33-5, and LD33-6; fig. 1) in-
volved 20–27 microsatellites, covering 13–17 cM. These
homozygosities indicated that the three affected individ-
uals inherited two copies of the same mutation from a
common ancestor—in this case, a grandmother—six
generations earlier. A recombination between D6S1553
and D6S1687 in LD33-6 determined that the telomeric
border of the LD region is D6S1687. In addition, a re-
combination centromeric to the LD locus, between
D6S1003 and D6S1010, in individual LD33-3 further
identified the centromeric border of the LD region, as
being D6S1003. These two recombinations (see fig. 1,
arrows) effectively reduced the critical LD interval, to
∼7 cM flanked centromerically by D6S1003 and telo-
merically by D6S1687.
Our second level of analyses looked at families whose
extended regions of homozygosities strongly supported
the presence of an LD locus in chromosome 6q24, even
though the small sizes of their families precluded LOD
scores from reaching significance. Homozygosities in
families LD20 and LD22 show the centromeric flanking
marker to be D6S308 and D6S403, respectively (see fig.
1). Data on LD22 are not shown. These observations
verify the general vicinity of the centromeric border of
the LD region, since D6S403 and D6S308 are !2 cM
from D6S1003. They lend support to the observation,
in family LD33, of D6S1003 as the centromeric flanking
marker.
Three proofs support D6S311 as the telomeric border
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Figure 1 Map of extended regions of homozygosity and recombinations (arrows) in six LD-affected subjects. Blackened bars denote
chromosome 6q23-25 regions of homozygosities in member LD15-4, member LD16-5, member LD20-1, and members LD33-3, LD33-5, and
LD33-6. Common regions of homozygosities locate the LD gene between D6S1003 and D6S311. The borders of homozygosities in members
LD33-3 and LD16-5 provide the centromeric (D6S1003) and telomeric (D6S311) flanking markers. To obtain the order of microsatellites in
chromosome 6q23-25, we used 27 YAC clones to construct an 8-cM YAC contig that oriented the microsatellites located in the interval between
D6S292 and D6S409. To determine the order of markers telomeric to D6S409, we analyzed phases and recombinations in members of the LD
families. Our results with regard to the order of microsatellites in the interval spanned by D6S292 and D6S420 were consistent with the
Whitehead Institute for Biomedical Research/MIT Center for Genome Research (1997) (http://www-genome.wi.mit.edu/) and Stanford Human
Genome Center (1997) (http://shgc-www.stanford.edu) physical maps. D6S409 was not represented in the Whitehead Institute map but was
illustrated in the Ge´ne´thon map (Chumakov et al. 1995; Dib et al. 1996). The Whitehead Institute map, on the other hand, placed D6S1003,
D6S1010, D6S1049, D6S1703, and D6S1042 (markers that were not included in the Ge´ne´thon map) centromeric to D6S311. The correct
location of D6S409 was determined by our YAC contig and was consistent with the order of markers in the Ge´ne´thon and CHLC-Marshfield
maps. According to our YAC contig, D6S1003 is telomeric to D6S409, and, according to the Whitehead Institute and Stanford physical maps,
the marker D6S1003 is centromeric to D6S311. On the basis of these maps and our YAC contig, we inferred that the location of D6S1003 is
between D6S409 and D6S311. These latter two markers, D6S409 and D6S311, and the markers between them—namely, D6S1003, D6S1010,
D6S1049, D6S1703, and D6S1042—define an interval of 2.7 cM, according to the Ge´ne´thon map (Chumakov et al. 1995; Dib et al. 1996)
and the CHLC-Marshfield map.
of the LD gene. First, homozygosities in family LD15
identify the telomeric border as D6S1553, and results
for family LD16 cut the LD region further and identify
D6S311 as the telomeric flanking marker (see fig. 1).
Second, another family, LD17, has loss of homozygosity
at the telomeric end in D6S311, but we were unable to
genotype for the new generation of markers in the in-
terval spanned by D6S1003 and D6S311, because of the
minute amounts of DNA obtained from archived par-
affin-embedded tissues. Although the genotypes for these
newmicrosatellites are missing, the existing data support
D6S311 as the telomeric flanking marker in family LD17
(data not shown). Third, a recombination between
D6S311 and D6S978 in family LD15 (see fig. 1, arrows)
provides further proof that D6S311 is the telomeric bor-
der of the disease gene.
In summary, we reduced the size of the LD interval
to 2.7 cM flanked by D6S1003 and D6S311, by (a)
correlations between recombinations and homozygosi-
ties in a new large family (LD33), which, by itself, in-
dependently proved linkage to chromosome 6q24 mi-
crosatellites, (b) extended area of homozygosities in
affected members of smaller families (LD15, LD16,
LD17, LD20, and LD22), and (c) a recombination in
family LD15.
What kind of gene might be responsible for Lafora
progressive myoclonus epilepsy? If the gene responsible
for LD is involved in the degradation pathways of gly-
coprotein metabolism (Lafora 1955; Schwarz and Yan-
off 1965a, 1965b; Yokoi et al. 1968; Sakai et al. 1970;
Gambetti et al. 1971; Schwarz 1977; Federico et al.
1980), the alpha fucosidase-2 gene (FUCA2), located on
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chromosome 6q24, would be a candidate gene. FUCA2
is tightly linked to the protein marker, plasminogen (Ei-
berg et al. 1984), which, in turn, is genetically linked to
chromosome 6q (Murray et al. 1987).
A second candidate gene that maps to chromosome
6q22.3-q24 is that for L-isoaspartyl/D-aspartyl protein
methyltransferase, or protein carboxyl methyltransfer-
ase 1 (PCMT1) (MacLaren et al. 1992), which is in-
volved in repair of proteins (Ota et al. 1988). PCMT1
catalyzes the transfer of a methyl group from S-adenosyl-
L-methionine to the free carboxyl groups of D-aspartyl
and L-isoaspartyl residues, which represent sites of co-
valent damage to aging proteins. LD may represent a
disorder of protein repair, and the “intracellular amyloid
inclusion bodies” could be evidence of impaired protein
repair (Tsai and Clarke 1994).
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